Neuroendocrine Carcinoma Market

Market Overview:

The 7 major neuroendocrine carcinoma markets reached a value of US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.4 Billion by 2034, exhibiting a growth rate (CAGR) of 6.14% during 2024-2034.

The neuroendocrine carcinoma market has been comprehensively analyzed in IMARC's new report titled "Neuroendocrine Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neuroendocrine carcinoma is a type of cancer originating from neuroendocrine cells, which are specialized cells that release hormones into the bloodstream. It can manifest with a variety of symptoms that depend on the location of the tumor and the hormones it secretes. Some of the common indications include abdominal pain, persistent cough or wheezing, changes in bowel movements, unexplained weight loss, flushing or redness of the skin, diarrhea, hormonal imbalances, palpable lumps or masses, fatigue, jaundice, etc. The diagnosis of neuroendocrine carcinoma involves a combination of clinical evaluation, imaging studies, histopathological analysis, and molecular testing. Initial assessment typically includes a thorough medical history, physical examination, and blood tests to evaluate hormone levels and overall health status. Various imaging techniques, such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) scans, etc., aid in locating the tumor, determining its size, and detecting metastases. Additionally, numerous molecular tests, including genetic profiling and assessment of specific biomarkers, may be conducted to guide treatment decisions and identify potential therapeutic targets.

The increasing incidences of specific genetic mutations or alterations that disrupt normal cell growth and division, thereby leading to the uncontrolled proliferation of neuroendocrine cells, are primarily driving the neuroendocrine carcinoma market. Furthermore, the rising prevalence of numerous associated risk factors, such as prolonged exposure to carcinogens, hormonal imbalances, chronic inflammation, etc., is acting as another significant growth-inducing factor. Additionally, the escalating application of embolization therapy to shrink the tumor and control symptoms is also creating a positive outlook for the market. This procedure involves blocking the blood supply to the tumor by injecting small particles or coils into the blood vessels that are feeding the tumor. Moreover, the emerging popularity of immune checkpoint inhibitors, including pembrolizumab and nivolumab, among patients with high tumor mutational burden or mismatch repair deficiency is further bolstering the market growth. Apart from this, the widespread adoption of multiparametric magnetic resonance imaging (MRI) techniques, such as diffusion-weighted imaging (DWI) and dynamic contrast-enhanced MRI (DCE-MRI), on account of their several associated benefits, including improved lesion identification, assessment of tumor aggressiveness, detection of metastases, etc., is expected to drive the neuroendocrine carcinoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the neuroendocrine carcinoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for neuroendocrine carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neuroendocrine carcinoma market in any manner.

Recent Developments:

• In September 2024, Abdera Therapeutics Inc. announced that ABD-147 had been granted Orphan Drug Designation by the U.S. FDA for the treatment of neuroendocrine carcinoma. ABD-147 is a next-generation precision radiopharmaceutical biologic therapy that delivers Actinium-225 (225Ac) to solid tumors that express DLL3, a protein found on the surface of neuroendocrine tumors but rarely on the surface of normal cells or tissues.
• In July 2024, Ipsen confirmed an expanded collaboration and license agreement with Exelixis, Inc. for the development of Cabometyx (cabozantinib) in advanced pancreatic neuroendocrine tumors (pNETs) and advanced extra-pancreatic neuroendocrine tumors (epNETs). The agreement is based on positive results from the CABINET Phase III trial, led by the Alliance for Clinical Trials in Oncology and sponsored by the National Cancer Institute (NCI), which compared Cabometyx to placebo in people with advanced pNETs or advanced epNETs whose disease had progressed after prior systemic therapy.
• In July 2024, Curium announced that it had submitted its 505(b)(2) New Drug Application for Lutetium Lu 177 Dotatate Injection, which, if approved by the U.S. FDA, would be intended for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
• In April 2024, Novartis announced that the FDA had approved Lutathera (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of pediatric patients aged 12 and up with somatostatin receptor-positive (SSTR+) GEP-NETs, which include foregut, midgut, and hindgut NETs. With this approval, Lutathera becomes the first medication specially assessed and approved for use in pediatric patients with GEP-NETs.
• In February 2024, RadioMedix, Inc. and Orano Med announced that AlphaMedix (212Pb-DOTAMTATE) had been granted Breakthrough Therapy Designation (BTD) by the U.S. FDA for the treatment of adult patients with progressive SSTR+ GEP-NETs that are not responsive to peptide receptor radionuclide therapy (PRRT) and are either unresectable or metastatic.

Key Highlights:

• Neuroendocrine carcinoma accounts for only 0.5% of all cancers.
• The prevalence is about 2/100,000, with a female predominance under the age of 50 due to the appendiceal position.
• The predominant locations are the gastrointestinal tract (62-67%) and the lung (22-27%).
• Metastatic disease makes up 12-22% of cases.
• The 5-year survival rate is primarily associated with stage: 93% in local disease, 74% in regional disease, and 19% in metastatic illness.

Drugs:

Iadademstat is a small oral drug that acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a strong differentiating impact in hematologic malignancies and neuroendocrine tumors. Iadademstat is being tested in a collaborative Phase II basket research with the Fox Chase Cancer Center, in combination with paclitaxel in relapsed/refractory neuroendocrine carcinomas.

Pembrolizumab is an anti-programmed death receptor-1 (PD-1) that improves the immune system's ability to detect and fight tumor cells. It is a humanized monoclonal antibody that inhibits the interaction of PD-1 and its ligands, PD-L1 and PD-L2, activating T lymphocytes and affecting both tumor and healthy cells.

Lenvatinib is an orally available multiple receptor tyrosine kinase inhibitor that inhibits the kinase activity of the vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).  Lenvatinib inhibits kinases involved in pathogenic angiogenesis, tumor growth, and cancer progression, such as FGFR1-4, PDGFRα, KIT, and RET.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the neuroendocrine carcinoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the neuroendocrine carcinoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current neuroendocrine carcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the neuroendocrine carcinoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the neuroendocrine carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the neuroendocrine carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of neuroendocrine carcinoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of neuroendocrine carcinoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of neuroendocrine carcinoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with neuroendocrine carcinoma across the seven major markets?
• What is the size of the neuroendocrine carcinoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of neuroendocrine carcinoma?
• What will be the growth rate of patients across the seven major markets?
   

Neuroendocrine Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for neuroendocrine carcinoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neuroendocrine carcinoma market?
• What are the key regulatory events related to the neuroendocrine carcinoma market?
• What is the structure of clinical trial landscape by status related to the neuroendocrine carcinoma market?
• What is the structure of clinical trial landscape by phase related to the neuroendocrine carcinoma market?
• What is the structure of clinical trial landscape by route of administration related to the neuroendocrine carcinoma market?